UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CONSERVATION AND SUSTAINABLE USE OF GRAPEVINE GENETIC RESOURCES IN THE CAUCASUS AND NORTHERN BLACK SEA REGION

Acta horticulturae, 2009-01 (827), p.155-158

2009

Volltextzugriff (PDF)

Ten quick tips for sequence-based prediction of protein properties using machine learning

PLoS computational biology, 2022-12, Vol.18 (12), p.e1010669-e1010669

2022

Volltextzugriff (PDF)

Ten quick tips for sequence-based prediction of protein properties using machine learning

PLoS computational biology, 2022-12, Vol.18 (12)

2022

Volltextzugriff (PDF)

Morphofunctional characteristics of endocrine nephropathy in primary aldosteronism

Urologiia i nefrologiia, 1989-07 (4), p.58

1989

Volltextzugriff (PDF)

Prospects for online adaptive radiation therapy (ART) for head and neck cancer

Radiation oncology (London, England), 2024-01, Vol.19 (1), p.4-4, Article 4

2024

Volltextzugriff (PDF)

Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE)

Frontiers in neurology, 2022, Vol.13, p.890638-890638

2022

Volltextzugriff (PDF)

A qualitative study on mixed experiences of discrimination and healthcare access among HIV-positive immigrants in Spain

BMC public health, 2021-02, Vol.21 (1), p.385-385, Article 385

2021

Volltextzugriff (PDF)

Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis

Clinical infectious diseases, 2012-03, Vol.54 (6), p.e51-e54

2012

Volltextzugriff (PDF)

1495P Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results

Annals of oncology, 2023-10, Vol.34, p.S843-S843

2023

Volltextzugriff (PDF)

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-11, Vol.33, p.S1567-S1568

2022

Volltextzugriff (PDF)

327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

Annals of oncology, 2022-11, Vol.33, p.S1570-S1571

2022

Volltextzugriff (PDF)

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Annals of oncology, 2022-09, Vol.33, p.S1421

2022

Volltextzugriff (PDF)

954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis

Annals of oncology, 2022-09, Vol.33, p.S983-S984

2022

Volltextzugriff (PDF)

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

Annals of oncology, 2021-12, Vol.32, p.S1414

2021

Volltextzugriff (PDF)

50 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S38-S39

2023

Volltextzugriff (PDF)

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2021-09, Vol.32, p.S1328-S1328

2021

Volltextzugriff (PDF)

64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1

ESMO open, 2024-03, Vol.9, p.102643, Article 102643

2024

Volltextzugriff (PDF)

OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e2-e3

2023

Volltextzugriff (PDF)

Late HIV diagnosis among immigrants in Spain vs. native-born Spaniards, 2010-15

European journal of public health, 2021-12, Vol.31 (6), p.1123-1128

2021

Volltextzugriff (PDF)

154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101493, Article 101493

2023

Volltextzugriff (PDF)

122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

Immuno-oncology technology, 2022-12, Vol.16, p.100234, Article 100234

2022

Volltextzugriff (PDF)

DEFINE REMOVING MECHANISM OF TART FLAVOR IN SUBTROPICAL PERSIMMON FRUITS NEEDED FOR PRESERVATION

The European Journal of Technical and Natural Sciences, 2018-07, p.11-15

2018

Volltextzugriff (PDF)

Inhibition of IL-4/IL-13 Does Not Enhance the Efficacy of Allergen Immunotherapy in Murine Allergic Airway Inflammation

International Archives of Allergy and Immunology, 2007-01, Vol.142 (2), p.165-174

2007

Volltextzugriff (PDF)

Oral cavity features in patients suffering from osteogenesis imperfecta

Georgian medical news, 2011-04 (193), p.34-41

2011

Volltextzugriff (PDF)

Diagnostic value of the procalcitonine test in purulent-septic complications of chest traumas

Georgian medical news, 2007-04 (145), p.33-36

2007

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)
Bücher
(1)

Sprache

Englisch
(23)
Russisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Humans
(5)
Adolescent
(3)
Female
(3)
Male
(3)
Acquired Immune Deficiency Syndrome
(2)
Adult
(2)
Aids
(2)
Biochemical Research Methods
(2)
Biochemistry & Molecular Biology
(2)
Health Aspects
(2)
Health Care
(2)
Health Care Access
(2)
Health Services
(2)
Hiv
(2)
Human Immunodeficiency Virus
(2)
Immigrants
(2)
Immunology
(2)
Mathematical & Computational Biology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(21)
Journals@Ovid
(11)
MEDLINE
(7)
Ingenta
(6)
IngentaConnect Journals
(4)
PAIS Index
(2)
Oxford Journals
(2)
Oxford Journals 2020 Medicine
(2)
Publisher or Other Site
(2)
SpringerLink Journals - AutoHoldings
(2)
Ebook Central Perpetual and DDA
(1)
De Gruyter eBooks
(1)
eBooks on EBSCOhost
(1)
JSTOR
(1)

9 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CONSERVATION AND SUSTAINABLE USE OF GRAPEVINE GENETIC RESOURCES IN THE CAUCASUS AND NORTHERN BLACK SEA REGION

Ten quick tips for sequence-based prediction of protein properties using machine learning

Ten quick tips for sequence-based prediction of protein properties using machine learning

Morphofunctional characteristics of endocrine nephropathy in primary aldosteronism

Prospects for online adaptive radiation therapy (ART) for head and neck cancer

Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE)

A qualitative study on mixed experiences of discrimination and healthcare access among HIV-positive immigrants in Spain

Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis

1495P Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

50 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1

OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1

Late HIV diagnosis among immigrants in Spain vs. native-born Spaniards, 2010-15

154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer

122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

DEFINE REMOVING MECHANISM OF TART FLAVOR IN SUBTROPICAL PERSIMMON FRUITS NEEDED FOR PRESERVATION

Inhibition of IL-4/IL-13 Does Not Enhance the Efficacy of Allergen Immunotherapy in Murine Allergic Airway Inflammation

Oral cavity features in patients suffering from osteogenesis imperfecta

Diagnostic value of the procalcitonine test in purulent-septic complications of chest traumas

Suchergebnisse filtern